Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Q1 2024 Earnings Presentation
42 slides from Sanofi Sa's earnings presentation, Apr 25, 2024
Slide 1: Business Finance Pipeline
Business Finance Pipeline Appendices
Slide 2: Q1 2024 Results
Business Finance Pipeline Appendices Q1 2024 Results April 25, 2024
Slide 3: Forward-looking statements
Business Finance Pipeline Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projecti
Slide 4: Agenda
Business Finance Pipeline Appendices Agenda 01 Business Paul Hudson 02 Finance Francois-Xavier Roger 03 Pipeline Houman Ashrafian 04 Q&A Brian Foard, Thomas Triomphe, Olivier Charmeil, Julie Van Ongevalle and Roy Papatheodorou 4 Investor Relations
Slide 5: Robust growth driven by portfolio transformation
Business Finance Pipeline Appendices Robust growth driven by portfolio transformation Pharma launches1 • Dupixent: continued strong growth Dupixent in all indications across geographies €0.6bn €2.8bn +91% • Pharma launches: sustained uptake +25% • Vaccines: boosted by Beyfortus Vaccines and flu phas
Slide 6: Dupixent: strong start and on track to deliver ~€13bn in 2024
Business Finance Pipeline Appendices Dupixent: strong start and on track to deliver～€13bn in 2024 Global Dupixent sales (€m) Q1 performance 2,835 Ex-US US Global growth Accelerated ex-US growth +25% (>50%) with indication expansion 2,316 #1 NBRx market share across ALL approved indications2 US 1,614
Slide 7: Dupixent: undisputed respiratory leadership
Business Finance Pipeline Appendices Dupixent: undisputed respiratory leadership Weekly NBRx1 across pulmonologists in the US 350 300 Continued scientific 250 leadership with 200 landmark VESTIGE study showing reduced airway 150 Competitor 1 inflammation and mucus 100 Competitor 2 plugging in asthma
Slide 8: Dupixent: committed to set a new Standard of Care in COPD
Business Finance Pipeline Appendices Dupixent: committed to set a new Standard of Care in COPD Opportunity to address Dupixent COPD PDUFA a large unmet medical need June 27, 2024 Progressive disease imposing relentless Established and most burden on patients and HC systems #1 First and only biologic
Slide 9: New launches: now 9% of total Biopharma sales
Business Finance Pipeline Appendices New launches: now 9% of total Biopharma sales 1 In €m Q1 sales 182 152 122 106 93 59 35 29 10 €788m, +150% 1. Sanofi sales excluding CHC. 9 Investor Relations
Slide 10: Important real-world results with All Infant programs confirming strong clinical-trial outcomes
Business Finance Pipeline Appendices Important real-world results with All Infant programs confirming strong clinical-trial outcomes USAa 90%5 Spaina (Navarre) Franceb 88.7%7 >80%4 Spaina, b (Galicia) 82%, 89%1,6 Spaina Spaina (Cataluña) (Murcia, Valencia, Valladolid) 87.6%3 a. Effectiveness (Case-c
Slide 11: Global Health Unit: making a difference for our patients in LMICs
Business Finance Pipeline Appendices Global Health Unit: making a difference for our patients in LMICs Impact our dedicated brand delivering Distribution Health system Scaling up its first boxes of treatments strengthening inclusive at accessible focused on businesses via Impact • Affordable prices
Slide 12: Finance
Business Finance Pipeline Appendices Finance Q1 2024
Slide 13: Portfolio transformation driving sales performance
Business Finance Pipeline Appendices Portfolio transformation driving sales performance Sales in Q1, in €m FY 2023 vs. 2022 Q1 2024 vs. 2023 +2% Total +5% +7% growth +7% 10,908 Rest of business 7% 4% -444 686 10,464 Launches 5% 3% -2% -5% 10,222 Impact of Aubagio, COVID-19 A23 @PUB Perf @CER A24 @CE
Slide 14: Q1 Group P&L
Business Finance Pipeline Appendices Q1 Group P&L €m Q1 2024 Q1 2023 % Change Sales growth Net Sales 10,464 10,222 +6.7% +6.7% Other revenues 654 641 +9.8% Gross margin Gross profit 7,694 7,784 +4.2% -2.6ppt, driven mainly by Gross margin % 73.5%1 76.1%1 Aubagio LoE, COVID-19 sales R&D (1,719) (1,56
Slide 15: Expected business dynamics in 2024
Business Finance Pipeline Appendices Expected business dynamics in 2024 Q2 2024 FY 2024 Sales • Dupixent, pharma launches: continued growth • Dupixent: expected to deliver ~€13bn • Beyfortus: no sales; early delivery/seasonality • Vaccines: expected to grow mid-single-digit • Aubagio: LoE impact EU
Slide 16: Pipeline
Business Finance Pipeline Appendices Pipeline
Slide 17: Pipeline: Q1 milestones
Business Finance Pipeline Appendices Pipeline: Q1 milestones Nexviazyme Pompe disease data at amlitelimab follow-up rilzabrutinib LUNA3 INBRX-101 WORLDSymposiumTM frexalimab MS phase 2 AD data at AAD phase 3 study in ITP acquisition phase 2 NEJM showed sustained achieved the primary Potential BIC re
Slide 18: Amlitelimab: durable clinical response supports Q12W dosing in atopic dermatitis
Business Finance Pipeline Appendices Amlitelimab: durable clinical response supports Q12W dosing in atopic dermatitis with safety profile maintained Persistence of response at week 52 after withdrawal at week 24 Overall incidence of TEAEs and AESIs was generally suggests potential normalization of i
Slide 19: Business Finance Pipeline
Business Finance Pipeline Appendices
Slide 20: Rilzabrutinib: recent positive data support the potential as a first and best-in-class BTK inhibitor
Business Finance Pipeline Appendices Rilzabrutinib: recent positive data support the potential as a first and best-in-class BTK inhibitor across immune diseases Primary endpoint met in ITP phase 3 study Encouraging high-dose data in asthma phase 2b study • New high-dose data showed higher trend of r
Slide 21: Oncology: selective patient-focused strategy
Business Finance Pipeline Appendices Oncology: selective patient-focused strategy Investing selectively in areas where we can best leverage immunology strengths Immune-mediated Proof of early execution to be presented at Focusing on critical unmet needs, MoAs immune-mediated mechanism of actions and
Slide 22: Rich pipeline newsflow
Business Finance Pipeline Appendices Rich pipeline newsflow amlitelimab - Hidradenitis suppurativa lunsekimig - Asthma amlitelimab - Alopecia areata TNFa/OX40L - Hidradenitis eclitasertib - Ulcerative colitis suppurativa amlitelimab - asthma Dupixent - CSU frexalimab - Systematic lupus SP0256 - RSV
Slide 23: Q&A session
Business Finance Pipeline Appendices Q&A session To ask a question By zoom By phone Any problems? Click on the Raise and lower your Email us: Raise hand icon hand: Dial *9 investor.relations@sanofi.com Check your audio device Unmute and mute is well connected your microphone: Dial *6
Slide 24: Finance appendices
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Finance appendices
Slide 25: Main biopharma sales
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Main biopharma sales Q1 2024 sales (€m) Growth Dupixent 2,835 24.9% Polio / Pertussis / Hib vaccines including Boosters 636 -0.5% Lantus 360 -15.4% Toujeo 321 18.0% Meningitis, Tra
Slide 26: Q1 Group CHC P&L
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Q1 Group CHC P&L €m Q1 2024 Q1 2023 % Change Sales growth Net Sales 1,525 1,495 +9.0% +9.0% due to Qunol acquisition and continued Other revenues 15 15 strong business performance
Slide 27: Q1 sales and EPS
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Q1 sales and EPS Currency impact Company sales Business EPS €475m +0.09 €16m -0.01 -€484m -€444m -0.13 -0.19 -€799m -0.22 -€922m -0.27 Q4 Q1 Q2 Q3 Q4 Q1 Q4 Q1 Q2 Q3 Q4 Q1 2022 2023
Slide 28: Net debt evolution in 2024
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Net debt evolution in 20241 € millions 349 8,534 83 456 78 7,793 252 -478 Net Debt FCF before Proceeds Asset Restructuring Acquisitions of Other4 Net Debt December 31, restructurin
Slide 29: Q1 2024 currency sensitivity and exposure
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Q1 2024 currency sensitivity and exposure 2024 Business EPS currency sensitivity Currency exposure on Q1 2024 sales Currency Variation Business EPS sensitivity Others 16.5% U.S. Do
Slide 30: Pipeline appendices
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Pipeline appendices
Slide 31: Pipeline Registration & Phase 3
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Pipeline Registration & Phase 3 Registration DupixentA Anti-IL-4/IL-13 mAb Chronic Obstructive Pulmonary Disease KevzaraA Anti-IL-6 mAb Polyarticular Juvenile Idiopathic Arthritis
Slide 32: Pipeline Phase 2
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Pipeline Phase 2 Immunology & Inflammation Transplant & Type 1 Diabetes DupixentA Anti-IL-4/IL-13 mAb Ulcerative Colitis frexalimabB,1 Anti-CD40L mAb Type 1 Diabetes itepekimabA An
Slide 33: Pipeline Phase 1
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Pipeline Phase 1 Immunology & Inflammation Oncology SAR444336 Non-beta IL-2 Synthorin Inflammatory indication SAR444881J Anti-ILT2 mAb Solid tumors SAR445611 Anti-CX3CR1 Nanobody V
Slide 34: ESG appendices
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations ESG appendices
Slide 35: Sanofi ESG Q1 achievements
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Sanofi ESG Q1 achievements Affordable access Ambition Progress Q1 2024 Q1 2023 Sanofi Reach 1.5 million NCD patients 57,889 patients treated 54,396 patients treated Global Health b
Slide 36: Sanofi ESG Q1 achievements
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Sanofi ESG Q1 achievements R&D for unmet needs Ambition Progress FY 2023 FY 2022 Sleeping Develop and supply innovative Data updated annually, next 1.5 million patients tested sick
Slide 37: Sanofi ESG Q1 achievements
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Sanofi ESG Q1 achievements Planet Care Ambition Progress Q1 2024 Q4 2023 Climate change - 55% reduction in scope 1&2 42% GHG reduction vs. 2019 38% GHG reduction vs. 2019 carbon fo
Slide 38: Sanofi ESG Q1 achievements
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Sanofi ESG Q1 achievements In and beyond the workplace Ambition Progress Q1 2024 Q4 2023 Global Gender Ambition of 50% of women 45% 44% balance in senior leadership roles by 2025 A
Slide 39: Sanofi ESG ratings
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Sanofi ESG ratings Rating agencies SCORE Climate 21.2 A 79/100 87/100 Change: A- B 4.5/5 3.47/5 65/100 Medium risk Water: A- A 21.5 78/100 New A/A- B 4.3/5 3.47/5 64/100 Score stab
Slide 40: Abbreviations
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Abbreviations AAT Alpha-1-Antitrypsine GAA Acid Alpha-Glucosidase NK Natural Killer AATD Alpha-1-Antitrypsine Deficiency GCS Glucosylceramide Synthase NKCE Natural Killer Cell Enga
Slide 41: Collaborations
Business Finance Pipeline Appendices Finance appendices Pipeline appendices ESG appendices Abbreviations Collaborations Collaborations Ref Name Developed in collaboration with… A Dupixent itepekimab Regeneron Kevzara B frexalimab ImmuNext C ExPEC9V Vaccine Janssen Pharmaceuticals, Inc., a Johnson &
Slide 42: Business Finance Pipeline
Business Finance Pipeline Appendices